Toleranzia AB (TOL.ST)
SEK 0.61
(0.33%)
SEK 0.61
(0.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -919 Thousand SEK | -101.3% |
| 2022 | 70.62 Million SEK | 29.1% |
| 2021 | 54.7 Million SEK | 118.62% |
| 2020 | 25.02 Million SEK | 93.39% |
| 2019 | 12.93 Million SEK | 51.23% |
| 2018 | 8.55 Million SEK | 68.93% |
| 2017 | 5.06 Million SEK | -20.19% |
| 2016 | 6.34 Million SEK | 392.4% |
| 2015 | 1.28 Million SEK | -6.24% |
| 2014 | 1.37 Million SEK | -8.89% |
| 2013 | 1.5 Million SEK | 32.51% |
| 2012 | 1.13 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 10.68 Million SEK | 44.44% |
| 2024 Q2 | 7.39 Million SEK | 50.74% |
| 2024 Q1 | 4.9 Million SEK | -57.02% |
| 2023 Q2 | 39.31 Million SEK | 94.03% |
| 2023 Q4 | 11.41 Million SEK | -42.33% |
| 2023 Q1 | 20.26 Million SEK | -23.65% |
| 2023 FY | 50.89 Million SEK | -27.94% |
| 2023 Q3 | 19.79 Million SEK | -49.65% |
| 2022 Q2 | 11.57 Million SEK | -28.38% |
| 2022 Q3 | 4.77 Million SEK | -58.77% |
| 2022 Q4 | 26.54 Million SEK | 456.28% |
| 2022 FY | 70.62 Million SEK | 29.1% |
| 2022 Q1 | 16.15 Million SEK | 40.28% |
| 2021 Q4 | 11.51 Million SEK | -21.31% |
| 2021 Q2 | 15.47 Million SEK | 18.36% |
| 2021 FY | 54.7 Million SEK | 118.62% |
| 2021 Q1 | 13.07 Million SEK | 68.76% |
| 2021 Q3 | 14.63 Million SEK | -5.41% |
| 2020 FY | 25.02 Million SEK | 93.39% |
| 2020 Q2 | 10.32 Million SEK | 165.97% |
| 2020 Q4 | 7.74 Million SEK | 152.9% |
| 2020 Q3 | 3.06 Million SEK | -70.32% |
| 2020 Q1 | 3.88 Million SEK | -41.79% |
| 2019 Q3 | 1.8 Million SEK | -34.85% |
| 2019 FY | 12.93 Million SEK | 51.23% |
| 2019 Q2 | 2.77 Million SEK | 64.54% |
| 2019 Q1 | 1.68 Million SEK | -34.55% |
| 2019 Q4 | 6.66 Million SEK | 268.63% |
| 2018 Q4 | 2.57 Million SEK | 54.59% |
| 2018 FY | 8.55 Million SEK | 68.93% |
| 2018 Q3 | 1.66 Million SEK | -30.82% |
| 2018 Q2 | 2.41 Million SEK | 26.87% |
| 2018 Q1 | 1.89 Million SEK | 24.39% |
| 2017 Q2 | 1.37 Million SEK | 21.51% |
| 2017 FY | 5.06 Million SEK | -20.19% |
| 2017 Q3 | 1.03 Million SEK | -24.25% |
| 2017 Q1 | 1.12 Million SEK | -20.22% |
| 2017 Q4 | 1.52 Million SEK | 47.1% |
| 2016 Q1 | 1.29 Million SEK | 147.95% |
| 2016 FY | 6.34 Million SEK | 392.4% |
| 2016 Q4 | 1.41 Million SEK | -16.55% |
| 2016 Q3 | 1.69 Million SEK | 48.66% |
| 2016 Q2 | 1.13 Million SEK | -12.06% |
| 2015 Q2 | 721.08 Thousand SEK | 156.83% |
| 2015 Q1 | 280.76 Thousand SEK | 226.01% |
| 2015 Q3 | 832.3 Thousand SEK | 15.42% |
| 2015 FY | 1.28 Million SEK | -6.24% |
| 2015 Q4 | 522.7 Thousand SEK | -37.2% |
| 2014 FY | 1.37 Million SEK | -8.89% |
| 2014 Q4 | 86.12 Thousand SEK | 0.0% |
| 2013 FY | 1.5 Million SEK | 32.51% |
| 2012 FY | 1.13 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | 113.941% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | -93.067% |
| BioGaia AB (publ) | 950.19 Million SEK | 100.097% |
| Enzymatica AB (publ) | 31.86 Million SEK | 102.884% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 76.442% |
| Gabather AB (publ) | - SEK | Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | -10111.111% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 56.217% |
| Nanexa AB (publ) | 59.15 Million SEK | 101.553% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | 105.732% |
| ODI Pharma AB | -1.34 Million SEK | 31.501% |
| Orexo AB (publ) | 549.9 Million SEK | 100.167% |
| Probi AB (publ) | 220.21 Million SEK | 100.417% |
| Swedencare AB (publ) | 164.8 Million SEK | 100.558% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 100.007% |
| Vivesto AB | -10.65 Million SEK | 91.376% |